1. Home
  2. Live Updates
  3. Genitourinary oncology

Live Breaking News & Updates on Genitourinary Oncology

Stay updated with breaking news from Genitourinary oncology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Merck's KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy | Business

RAHWAY, N.J. (BUSINESS WIRE) Jan 27, 2024 ....

United States , Peter Dannenbaum , Damini Chokshi , Tonik Choueiri , Michael Mcardle , Nancy Kohlberg , Julie Cunningham , Merck Research Laboratories , Exchange Commission , Harvard Medical School , Lank Center , American Society Of Clinical Oncology , Dana Farber Cancer Institute , European Union , Akeso Inc , Statement Of Merck Co Inc , Asco Gu Press Program , Merck Co Inc , Clinical Oncology , Cancers Symposium , Genitourinary Oncology , Harvard Medical , Marjorie Green , Merck Research , Positive Score , Selected Important Safety ,

Immunotherapy post-surgery found to improve overall survival for kidney cancer

Immunotherapy post-surgery found to improve overall survival for kidney cancer
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

United States , Toni Choueiri , Lank Center , Dana Farber Cancer Institute , American Society Of Clinical Oncology , Dana Farber Cancer , Genitourinary Oncology , American Society , Clinical Oncology , Genitourinary Cancer Symposium ,

Atezolizumab Plus Cabozantinib Improves PFS Over Novel Hormonal Therapy in mCRPC

A significant progression-free survival improvement was achieved with cabozantinib plus atezolizumab vs second-line novel hormonal therapy in mCRPC. ....

Neeraj Agarwal , Global Health Status , University Of Utah , European Organization For Research , Genitourinary Oncology Gu Program , Huntsman Cancer Institute , Genitourinary Oncology , Investigational Therapeutics , European Organization , Cancer Quality , Cabozantinib Plus Atezolizumab , Metastatic Castration Resistant Prostate Cancer , 2024 Genitourinary Cancers Symposium , Phase 3 Contact 02 Trial ,

Cabometyx, Tecentriq Combo Improves Time to Progression in mCRPC

Cabometyx plus Tecentriq led to improved progression-free survival compared with novel hormonal therapy in patients with metastatic castration-resistant prostate cancer. ....

Neeraj Agarwal , Cabometyx Tecentriq , Global Health Status , European Organization For Research , University Of Utah , Genitourinary Oncology Gu Program , Huntsman Cancer Institute , Genitourinary Oncology , Investigational Therapeutics , European Organization , Cancer Quality , Global Health , Prostate Cancer , Metastatic Castration Resistant Prostate Cancer , Asco Gu24 ,

Blood Test Distinguishes Neuroendocrine Subtype of Advanced Prostate Cancer

Blood test uses cell-free DNA methylation to quantify tumor burden and distinguish neuroendocrine prostate cancer from prostate adenocarcinoma. ....

United Kingdom , United States , Ricerca Sul Cancro , Himisha Beltran , Francesca Demichelis , V Foundation , Division Of Molecular , Doris Duke Foundation , Lank Center , National Cancer Institute , University Of Trento , Safeway Foundation , Prostate Cancer Foundation , Cancer Research United Kingdom , Dana Farber Cancer Institute , Institute For Prostate Cancer Research , United States Department Of Defense , Cancer Discovery , Genitourinary Oncology , Cellular Oncology , Dana Farber Cancer , United States Department , Prostate Cancer , Dana Farber Cancer Institute , Press Release ,